Want to see SE:BACTI.B full AI Analyst Report?
Top Page
Bactiguard Holding AB
(BACTI.B)
Select Model
Select Model
Rating:53Neutral
Price Target:
kr15.50
▼(-19.69% Downside)
Action:Reiterated
Date:10/24/26
The score is driven primarily by improving fundamentals (better margins and notably stronger operating/free cash flow with manageable leverage) but is capped by still-unproven profitability and historically volatile results. Technicals add a mild headwind (below key moving averages and negative MACD), and valuation is pressured by negative earnings (negative P/E).
Positive Factors
Improving Cash Generation
The return to positive operating and free cash flow strengthens internal funding capacity and reduces reliance on external financing. If maintained, better cash conversion can support product development, partner implementation, and regulatory activity while providing greater resilience through normal business fluctuations.
Negative Factors
Unproven Profitability
Despite substantial improvement from earlier losses, the company has not yet demonstrated durable operating profitability or positive shareholder returns. Continued losses could limit internally funded growth, weaken confidence in the business model, and make results more sensitive to execution and adoption timing.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Cash Generation
The return to positive operating and free cash flow strengthens internal funding capacity and reduces reliance on external financing. If maintained, better cash conversion can support product development, partner implementation, and regulatory activity while providing greater resilience through normal business fluctuations.
Read all positive factors
Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr551.94M
Dividend YieldN/A
Average Volume (3M)4.04K
Price to Earnings (P/E)87.5
Beta (1Y)0.31
Revenue Growth-0.51%
EPS GrowthN/A
CountrySE
Employees159
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.18
Shares Outstanding31,043,884
10 Day Avg. Volume7,899
30 Day Avg. Volume4,037
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.21
Revenue Forecast (FY)kr215.82M
Bactiguard Holding AB Business Overview & Revenue Model
Company Description
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HA...
How the Company Makes Money
Bactiguard makes money primarily through (1) licensing its infection-prevention coating technology to medical device manufacturers and (2) selling coated medical devices in certain product categories/markets, depending on how products are commerci...
Bactiguard Holding AB Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 214.73M | 215.92M | 243.68M | 203.99M | 223.56M | 169.49M |
| Gross Profit | 100.12M | 184.65M | 207.71M | 139.98M | 180.14M | 130.80M |
| EBITDA | 48.72M | 45.15M | 24.99M | -89.98M | -543.00K | -5.94M |
| Net Income | 6.02M | -7.84M | -29.82M | -138.38M | -52.88M | -58.77M |
Balance Sheet | ||||||
| Total Assets | 524.24M | 545.06M | 655.91M | 662.17M | 807.70M | 849.29M |
| Cash, Cash Equivalents and Short-Term Investments | 55.05M | 44.26M | 116.73M | 123.22M | 197.73M | 217.59M |
| Total Debt | 153.75M | 162.92M | 227.77M | 233.10M | 238.70M | 247.96M |
| Total Liabilities | 210.91M | 230.13M | 327.57M | 309.00M | 311.99M | 307.84M |
| Stockholders Equity | 313.33M | 314.93M | 328.34M | 353.18M | 495.71M | 541.45M |
Cash Flow | ||||||
| Free Cash Flow | 27.59M | -7.21M | 10.21M | -60.94M | -7.86M | -38.00K |
| Operating Cash Flow | 30.38M | -1.49M | 24.99M | -52.33M | 3.06M | 7.26M |
| Investing Cash Flow | -2.79M | -5.72M | -14.78M | -8.61M | -10.92M | -7.29M |
| Financing Cash Flow | -13.31M | -62.74M | -21.20M | -11.84M | -13.89M | 205.83M |
Bactiguard Holding AB Technical Analysis
Positive
19.30
Price Trends
15.72
Positive
15.89
Negative
16.23
Negative
Market Momentum
-0.10
Positive
50.80
Neutral
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Positive. The current price of 19.3 is above the 20-day moving average (MA) of 15.61, above the 50-day MA of 15.72, and above the 200-day MA of 16.23, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 50.80 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | kr73.00B | 25.79 | 9.13% | 1.77% | -3.90% | 37.73% | |
53 Neutral | kr551.94M | 87.50 | 1.93% | ― | -0.51% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr254.04M | -6.03 | -20.71% | ― | 1.43% | 6.65% | |
44 Neutral | kr432.34M | -3.87 | -37.43% | ― | 27.40% | 26.07% | |
42 Neutral | kr370.04M | -7.39 | ― | ― | -2.61% | -0.28% |
* Healthcare Sector Average
SE:BACTI.B
Bactiguard Holding AB
15.45
-0.85
-5.21%
SE:GETI.B
Getinge
269.50
51.65
23.71%
SE:SEZI
Senzime AB
2.83
-3.08
-52.12%
SE:INTEG.B
Integrum AB Class B
8.45
0.26
3.24%
SE:PRO
Promimic AB
9.80
-3.30
-25.19%
SE:OSSD
OssDsign AB
3.38
-9.85
-74.47%
Bactiguard Holding AB Corporate Events
Bactiguard’s Partnership-Driven Growth Delivers Strong Q3 Turnaround
Oct 22, 2026
Bactiguard Holding AB reported a strong third quarter 2026, with total revenue rising 20.6% to SEK 58.4 million and net sales up 21.2% to SEK 55.1 million, driven mainly by its partnership model. Operating profit swung to SEK 6.8 million from a lo...
Bactiguard Sets Date for Q3 2026 Report and Investor Audiocast
Oct 16, 2026
Bactiguard Holding AB will publish its interim report for the third quarter of 2026 on 22 October at 07:00 CEST. The MedTech firm is organizing an audiocast and conference call the same day at 11:00 CEST, where CEO Christine Lind and CFO Patrick B...
Bactiguard Data Highlight Durable, Low-Silver Coating for Orthopedic Implants
Sep 17, 2026
Bactiguard has unveiled new data on its noble metal coating technology, reinforcing its distinct and durable performance on orthopedic implants. Presented at major international arthroplasty and infection conferences, the findings position the com...
Bactiguard Adjusts Share Structure to Support 2026 Incentive Plan
Jul 31, 2026
Bactiguard Holding AB, a Stockholm-based MedTech firm listed on Nasdaq Stockholm’s Small Cap segment, develops noble metal coating technologies that prevent infections on medical devices and offers wound care products across orthopedics, car...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.